Compositions for treating sorafenib-resistant liver cancer and Methods for providing information on treating sorafenib-resistant liver cancer

摘要

The present invention relates to a composition for the treatment of sorafenib-resistant liver cancer and a method of providing information on the treatment of sorafenib-resistant liver cancer, and more particularly, a composition for treatment of sorafenib-resistant liver cancer including NK cells, and a conch confirmed that CEACAM1 expression is reduced It relates to a method of providing information on treatment of liver cancer comprising providing information on the effect of administration of NK cells to a patient with phenib-resistant liver cancer. In the present invention, it was confirmed that CEACAM1 expression was decreased in SR-Huh7 cells having sorafenib resistance, and when NK cells, especially NK cells treated with anti-CEACAM1 antibody and SR-Huh7 cells were co-cultured, Since it was confirmed that the SR-Huh7 cytotoxic effect was increased, the administration of NK cells can be effectively applied to the treatment of sorafenib-resistant liver cancer.